Associated Papers
DAPK2 Regulates PKM2 Phosphorylation at Threonine 45 to Facilitate Disturbed Flow-Induced Atherosclerosis.
Guo S et al.
Circulation, 2026
Frequent EPHA2 receptor mutations in cholangiocarcinoma disrupt receptor forward signaling supporting a tumor suppressor role.
Koutouan E et al.
Biochimica Et Biophysica Acta. Molecular Cell Research, 2026
Crosstalk among canonical Wnt and Hippo pathway members in skeletal muscle and at the neuromuscular junction.
Hashemolhosseini S et al.
Neural Regeneration Research, 2025
Vertical inhibition of p110α/AKT and N-cadherin enhances treatment efficacy in PIK3CA-aberrated ovarian cancer cells.
Zhang S et al.
Molecular Oncology, 2025
Frequent EPHA2 receptor mutations in cholangiocarcinoma disrupt receptor forward signaling supporting a tumor suppressor role.
Koutouan E et al.
Biorxiv : the Preprint Server for Biology, 2025
Enhanced ferroptosis sensitivity promotes the formation of highly myopic cataract via the DDR2-Hippo pathway.
Guo D et al.
Cell Death & Disease, 2025
YAP-driven malignant reprogramming of oral epithelial stem cells at single cell resolution.
Faraji F et al.
Nature Communications, 2025
Decoding Missense Variants by Incorporating Phase Separation via Machine Learning.
Feng M et al.
Nature Communications, 2024
Yap/Taz activity is associated with increased expression of phosphoglycerate dehydrogenase that supports myoblast proliferation.
Meinhold M et al.
Cell and Tissue Research, 2024
The L27 Domain of MPP7 enhances TAZ-YY1 Cooperation to Renew Muscle Stem Cells.
Shao A et al.
Biorxiv : the Preprint Server for Biology, 2023
Systematic in vivo candidate evaluation uncovers therapeutic targets for LMNA dilated cardiomyopathy and risk of Lamin A toxicity.
Tan CY et al.
Journal of Translational Medicine, 2023
Identification and experimental validation of druggable epigenetic targets in hepatoblastoma.
Clavería-Cabello A et al.
Journal of Hepatology, 2023
YAP silencing by RB1 mutation is essential for small-cell lung cancer metastasis.
Wu Z et al.
Nature Communications, 2023
FOXM1, MEK, and CDK4/6: New Targets for Malignant Peripheral Nerve Sheath Tumor Therapy.
Voigt E et al.
International Journal of Molecular Sciences, 2023
NOTCH signalling - a core regulator of bile duct disease?
Martinez Lyons A et al.
Disease Models & Mechanisms, 2023
Transforming Growth Factor Beta Promotes Inflammation and Tumorigenesis in Smad4-Deficient Intestinal Epithelium in a YAP-Dependent Manner.
Liu L et al.
Advanced Science (weinheim, Baden-wurttemberg, Germany), 2023
Genome-wide mapping of cancer dependency genes and genetic modifiers of chemotherapy in high-risk hepatoblastoma.
Fang J et al.
Nature Communications, 2023
Multiomics characterization of mouse hepatoblastoma identifies yes-associated protein 1 target genes.
Rodríguez TC et al.
Hepatology (baltimore, Md.), 2023
Aberrant expression of NPPB through YAP1 and TAZ activation in mesothelioma with Hippo pathway gene alterations.
Sato T et al.
Cancer Medicine, 2023
Importance of the filamin A-Sav1 interaction in organ size control: evidence from transgenic mice.
Zhang H et al.
The International Journal of Developmental Biology, 2023
Yap governs a lineage-specific neuregulin1 pathway-driven adaptive resistance to RAF kinase inhibitors.
Garcia-Rendueles MER et al.
Molecular Cancer, 2022
RhoA-ROCK competes with YAP to regulate amoeboid breast cancer cell migration in response to lymphatic-like flow.
Mohammadalipour A et al.
Faseb Bioadvances, 2022
Genomic Hippo Pathway Alterations and Persistent YAP/TAZ Activation: New Hallmarks in Head and Neck Cancer.
Faraji F et al.
Cells, 2022
Loss of the wild-type KRAS allele promotes pancreatic cancer progression through functional activation of YAP1.
Yan H et al.
Oncogene, 2021
RASSF1A-Mediated Suppression of Estrogen Receptor Alpha (ERα)-Driven Breast Cancer Cell Growth Depends on the Hippo-Kinases LATS1 and 2.
Roßwag S et al.
Cells, 2021
pVHL promotes lysosomal degradation of YAP in lung adenocarcinoma.
Hu L et al.
Cellular Signalling, 2021
TAZ-CAMTA1 and YAP-TFE3 alter the TAZ/YAP transcriptome by recruiting the ATAC histone acetyltransferase complex.
Merritt N et al.
Elife, 2021
YAP1 Withdrawal in Hepatoblastoma Drives Therapeutic Differentiation of Tumor Cells to Functional Hepatocyte-Like Cells.
Smith JL et al.
Hepatology (baltimore, Md.), 2021
IQGAP1 Is a Scaffold of the Core Proteins of the Hippo Pathway and Negatively Regulates the Pro-Apoptotic Signal Mediated by This Pathway.
Quinn NP et al.
Cells, 2021
Mutations and Copy Number Abnormalities of Hippo Pathway Components in Human Cancers.
He Z et al.
Frontiers in Cell and Developmental Biology, 2021
Telomere dysfunction activates YAP1 to drive tissue inflammation.
Chakravarti D et al.
Nature Communications, 2020
Comparison of tumor-associated YAP1 fusions identifies a recurrent set of functions critical for oncogenesis.
Szulzewsky F et al.
Genes & Development, 2020
Small Molecule Dysregulation of TEAD Lipidation Induces a Dominant-Negative Inhibition of Hippo Pathway Signaling.
Holden JK et al.
Cell Reports, 2020
YAP1/TAZ drives ependymoma-like tumour formation in mice.
Eder N et al.
Nature Communications, 2020
Gain-of-Function RHOA Mutations Promote Focal Adhesion Kinase Activation and Dependency in Diffuse Gastric Cancer.
Zhang H et al.
Cancer Discovery, 2020
The WW domains dictate isoform-specific regulation of YAP1 stability and pancreatic cancer cell malignancy.
Guo Q et al.
Theranostics, 2020
Somatic Hypermutation of the YAP Oncogene in a Human Cutaneous Melanoma.
Zhang X et al.
Molecular Cancer Research : Mcr, 2019
β-Catenin and Yes-Associated Protein 1 Cooperate in Hepatoblastoma Pathogenesis.
Min Q et al.
The American Journal of Pathology, 2019
mTOR inhibition affects Yap1-β-catenin-induced hepatoblastoma growth and development.
Molina L et al.
Oncotarget, 2019
NUAK2 is a critical YAP target in liver cancer.
Yuan WC et al.
Nature Communications, 2018
Hepatocyte-Derived Lipocalin 2 Is a Potential Serum Biomarker Reflecting Tumor Burden in Hepatoblastoma.
Molina L et al.
The American Journal of Pathology, 2018
TLR3 Mediates Repair and Regeneration of Damaged Neonatal Heart through Glycolysis Dependent YAP1 Regulated miR-152 Expression.
Wang X et al.
Cell Death and Differentiation, 2018
Targeting the Hippo Pathway Is a New Potential Therapeutic Modality for Malignant Mesothelioma.
Sekido Y
Cancers, 2018
RUNX1 and RUNX3 protect against YAP-mediated EMT, stem-ness and shorter survival outcomes in breast cancer.
Kulkarni M et al.
Oncotarget, 2018
YAP and TAZ regulate adherens junction dynamics and endothelial cell distribution during vascular development.
Neto F et al.
Elife, 2018
Activation of Yap1/Taz signaling in ischemic heart disease and dilated cardiomyopathy.
Hou N et al.
Experimental and Molecular Pathology, 2017